| Ms Patrina Celeste Minella, PEL ILLINOIS SLP | |
|
501 7th St, Rockford, IL 61104-1242 | |
| (815) 966-3000 | |
| Not Available |
| Full Name | Ms Patrina Celeste Minella |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 501 7th St, Rockford, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063052587 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 1187003 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Patrina Celeste Minella, PEL ILLINOIS SLP 1712 White Ave, Beloit, WI 53511-4732 Ph: (608) 346-7644 | Ms Patrina Celeste Minella, PEL ILLINOIS SLP 501 7th St, Rockford, IL 61104-1242 Ph: (815) 966-3000 |
News Archive
A recent study assesses the serological and cellular responses to Pfizer's BNT162b2 mRNA vaccine in people aged 80-96 years.
The Wall Street Journal reports that a senior FDA regulator is seeking stronger warnings about a class of blood pressure drugs that may be linked to higher cancer rates. Meanwhile, The New York Times details how a doctor hired by Merck to test a diabetes drug in rats found a possible link to pancreatic cancer, a discovery that turned the doctor into a crusader.
On Dec. 21, the U.S. Food and Drug Administration approved Juxtapid (lomitapide) to reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Juxtapid is intended for use in combination with a low fat diet and other lipid-lowering treatments.
A new program guide, published by the Centers for Disease Control and Prevention (CDC), features the Maryland Patients, Pharmacists, Partnerships (P3) as an effective model of how health care teams that include pharmacists can improve the outcomes of patients with chronic diseases.
Researchers at the University of North Carolina at Chapel Hill School of Medicine have identified a compound that could be modified to treat one of the most deadly types of cancer, and discovered how a particular gene mutation contributes to tumor growth.
› Verified 9 days ago
Kathleen A Franzen, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4820 Carol Ct, Rockford, IL 61108 Phone: 815-229-2176 Fax: 815-921-0303 | |
Inna Natanova, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5222 Spring Creek Rd, Rockford, IL 61114 Phone: 224-619-5666 | |
Elizabeth Dorothy Young, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1750 Madron Rd, Rockford, IL 61107 Phone: 815-229-2492 | |
Lois Holmes Vatch, M.A./CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3470 N Alpine Rd, Rockford, IL 61114 Phone: 815-639-1015 | |
Bethany Halbrader, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5666 E State St, Rockford, IL 61108 Phone: 815-381-7721 | |
Mrs. Judith L Ruch, Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 650 N Main St, Rockford, IL 61103 Phone: 815-965-6745 Fax: 815-968-9563 |